A technique combining digital PCR and CRISPR based detection with a LAMP-style simple amplification detects SARS-CoV-2 and other viruses quickly and specifically without the time consuming and costly need for thermal cycling of RT-PCR.
Researchers have corrected the sickle cell disease-causing variant in mice and in a human cell line using a base editor without requiring double-stranded DNA breaks or inserting new segments of DNA into the genome.
Amgen's Lumakras, a small molecule just approved for clinical use by the FDA, becomes the first targeted therapy for lung cancer patients with KRAS mutations, an urgently needed option for patients with limited therapeutic options.
Roche and Wave's Huntington's disease ASO trials failed earlier this year, but researchers in the field remain positive that a more effective therapy will be developed in the not too distant future.
After analyzing 330 metabolism genes in a pre-clinical model of glioblastoma, MD Anderson researchers discovered that several enzymes involved in fatty acid metabolism were important for glioblastoma cells.
To harness siRNA’s gene silencing capabilities, scientists must get it into the appropriate cells, which requires attaching it to a larger molecule to protect it during delivery. Peptide carriers are an attractive tool for delivering siRNA, because they are affordable and easy to modify.
Memorial Sloan Kettering spin-out Paige will partner with Quest Diagnostics to develop precise AI-driven cancer assessment tools to speed up and improve diagnosis for patients with a range of solid tumors.
A new study finds that nearly a year after recovering from COVID-19, the body’s bone marrow plasma cells still make active antibodies against the virus. The findings appear to suggest that antibody production does not wane over time to the point of offering no protection.
The researchers used structural biology to map, at atomic scale, how certain classes of neutralizing antibodies bind to the original pandemic strain of SARS-CoV-2, the virus that causes COVID-19.
The progress was made in the study of a gene responsible for an inner-ear protein, otoferlin. Mutations in otoferlin are linked to severe congenital hearing loss, a common type of deafness in which patients can hear almost nothing.